β-d-N4-羟基胞苷（前药莫努匹拉韦的母体核苷）在严重急性呼吸综合征冠状病毒2感染患者非血浆区室中的药代动力学。
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
作者信息
FitzGerald Richard, Dickinson Laura, Else Laura, Fletcher Thomas, Hale Colin, Amara Alieu, Walker Lauren, Penchala Sujan Dilly, Lyon Rebecca, Shaw Victoria, Greenhalf William, Bullock Katie, Lavelle-Langham Lara, Reynolds Helen, Painter Wendy, Holman Wayne, Ewings Sean, Griffiths Gareth, Khoo Saye
机构信息
National Institute for Health Research Royal Liverpool & Broadgreen Clinical Research Facility, Liverpool University Hospital NHS Foundation Trust, Liverpool, United Kingdom.
Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom.
出版信息
Clin Infect Dis. 2022 Aug 24;75(1):e525-e528. doi: 10.1093/cid/ciac199.
Abstract
ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at SARS-CoV-2 transmission sites in 12 patients enrolled in AGILE Candidate-Specific Trial-2. Saliva, nasal, and tear NHC concentrations were 3%, 21%, and 22% that of plasma. Saliva and nasal NHC were significantly correlated with plasma (P < .0001). Clinical Trials Registration. NCT04746183.
摘要
β-d-N4-羟基胞苷（NHC）是抗新冠病毒药物莫努匹拉韦的母体核苷，在参与AGILE候选特异性试验-2的12名患者的新冠病毒传播部位进行了定量分析。唾液、鼻腔和泪液中的NHC浓度分别为血浆浓度的3%、21%和22%。唾液和鼻腔中的NHC与血浆显著相关（P < 0.0001）。临床试验注册编号：NCT04746183。
相似文献
1
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Clin Infect Dis. 2022 Aug 24;75(1):e525-e528. doi: 10.1093/cid/ciac199.
2
New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
Antiviral Res. 2024 May;225:105871. doi: 10.1016/j.antiviral.2024.105871. Epub 2024 Mar 28.
3
Molnupiravir and Its Antiviral Activity Against COVID-19.
Front Immunol. 2022 Apr 4;13:855496. doi: 10.3389/fimmu.2022.855496. eCollection 2022.
4
Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier.
EBioMedicine. 2023 Sep;95:104748. doi: 10.1016/j.ebiom.2023.104748. Epub 2023 Aug 4.
5
Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
Viruses. 2022 Jun 20;14(6):1345. doi: 10.3390/v14061345.
6
Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
Environ Mol Mutagen. 2022 Jan;63(1):37-63. doi: 10.1002/em.22471.
7
Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
J Med Virol. 2022 Jul;94(7):3006-3016. doi: 10.1002/jmv.27730. Epub 2022 Apr 2.
8
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
J Biol Chem. 2021 Jul;297(1):100770. doi: 10.1016/j.jbc.2021.100770. Epub 2021 May 11.
9
A Nanopore Based Molnupiravir Sensor.
ACS Sens. 2022 May 27;7(5):1564-1571. doi: 10.1021/acssensors.2c00447. Epub 2022 Apr 15.
10
Evaluation of N4-hydroxycytidine incorporation into nucleic acids of SARS-CoV-2-infected host cells by direct measurement with liquid chromatography-mass spectrometry.
Nucleosides Nucleotides Nucleic Acids. 2024;43(8):813-821. doi: 10.1080/15257770.2024.2346550. Epub 2024 May 13.
引用本文的文献
1
Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis.
BMJ. 2025 May 29;389:e081165. doi: 10.1136/bmj-2024-081165.
2
Pharmacokinetics and bioequivalence of a molnupiravir tablet formulation compared with the molnupiravir capsule formulation in healthy adult participants-a randomized, open-label, three-period, crossover study.
Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0143424. doi: 10.1128/aac.01434-24. Epub 2025 Feb 6.
3
Assessment of pharmacokinetics and tolerability following single-dose administration of molnupiravir in participants with hepatic or renal impairment.
Clin Transl Sci. 2024 Dec;17(12):e70073. doi: 10.1111/cts.70073.
4
Uridine-cytidine kinase 2 potentiates the mutagenic influence of the antiviral β-d-N4-hydroxycytidine.
Nucleic Acids Res. 2023 Dec 11;51(22):12031-12042. doi: 10.1093/nar/gkad1002.
5
White targeted chromatographic screening method of Molnupiravir and its metabolite with degradation kinetics characterization and in-silico toxicity.
Sci Rep. 2023 Oct 20;13(1):17919. doi: 10.1038/s41598-023-44756-6.
6
Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat.
Commun Med (Lond). 2023 Oct 19;3(1):150. doi: 10.1038/s43856-023-00383-w.
7
Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants.
Clin Transl Sci. 2023 Oct;16(10):1947-1956. doi: 10.1111/cts.13602. Epub 2023 Aug 8.
8
Exploring the Protective Effect of Food Drugs against Viral Diseases: Interaction of Functional Food Ingredients and SARS-CoV-2, Influenza Virus, and HSV.
Life (Basel). 2023 Feb 1;13(2):402. doi: 10.3390/life13020402.
本文引用的文献
1
The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva.
J Pharm Biomed Anal. 2021 Nov 30;206:114356. doi: 10.1016/j.jpba.2021.114356. Epub 2021 Sep 2.
2
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
J Antimicrob Chemother. 2021 Nov 12;76(12):3286-3295. doi: 10.1093/jac/dkab318.
3
AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter.
Trials. 2021 Jul 26;22(1):487. doi: 10.1186/s13063-021-05458-4.
4
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.
Nat Microbiol. 2021 Jan;6(1):11-18. doi: 10.1038/s41564-020-00835-2. Epub 2020 Dec 3.
5
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Sci Transl Med. 2020 Apr 29;12(541). doi: 10.1126/scitranslmed.abb5883. Epub 2020 Apr 6.
6
The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection.
Antiviral Res. 2019 Nov;171:104597. doi: 10.1016/j.antiviral.2019.104597. Epub 2019 Sep 5.
7
Factors influencing the saliva/plasma ratio of drugs.
Ann N Y Acad Sci. 1993 Sep 20;694:128-42. doi: 10.1111/j.1749-6632.1993.tb18347.x.
Zotero 插件